Gate2Brain is a biotechnology company developing breakthrough solutions to enable the delivery of therapeutics across the blood–brain barrier (BBB), one of the main challenges in treating central nervous system (CNS) diseases. By overcoming this critical limitation, Gate2Brain aims to unlock the full potential of a wide range of drugs that otherwise fail to reach the brain in effective concentrations. The company has developed a proprietary platform based on innovative shuttle peptides capable of transporting diverse therapeutic modalities—including small molecules, antibodies, proteins, and nucleic acids—into the brain. These peptides can be conjugated or fused to existing drugs, enhancing their brain penetration while maintaining specificity and safety. Gate2Brain’s technology has generated strong preclinical validation, demonstrating improved biodistribution and therapeutic efficacy in models of brain tumors and neurological disorders. The company is advancing an internal pipeline focused on high unmet medical needs, particularly in neuro-oncology and rare CNS diseases. In parallel, Gate2Brain actively pursues strategic partnerships with pharmaceutical and biotech companies to apply its BBB delivery platform to external assets, enabling CNS expansion strategies and accelerating drug development. Its approach offers a versatile and scalable solution to transform the treatment landscape for patients with brain-related conditions. Founded by a team with strong expertise in peptide chemistry, drug delivery, and translational research, Gate2Brain is committed to bridging the gap between innovation and patient impact, bringing new therapeutic opportunities to the clinic.